Barclays PLC Has $606,000 Position in Bioventus Inc. (NYSE:BVS)

Barclays PLC raised its stake in shares of Bioventus Inc. (NYSE:BVS) by 24.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 50,654 shares of the company’s stock after purchasing an additional 9,854 shares during the period. Barclays PLC’s holdings in Bioventus were worth $606,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Squarepoint Ops LLC raised its holdings in Bioventus by 13.8% in the 2nd quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock worth $150,000 after acquiring an additional 3,170 shares during the period. Virtus Fund Advisers LLC bought a new position in shares of Bioventus in the third quarter worth about $42,000. Quest Partners LLC acquired a new position in shares of Bioventus during the 3rd quarter worth about $51,000. Quarry LP bought a new stake in Bioventus during the 3rd quarter valued at approximately $59,000. Finally, Covestor Ltd acquired a new stake in Bioventus in the 3rd quarter valued at approximately $69,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Katrina J. Church sold 2,535 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $26,693.55. Following the completion of the sale, the senior vice president now owns 47,264 shares of the company’s stock, valued at approximately $497,689.92. This trade represents a 5.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Mark Leonard Singleton sold 10,733 shares of Bioventus stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49. Following the completion of the transaction, the chief financial officer now owns 105,162 shares of the company’s stock, valued at $1,107,355.86. This trade represents a 9.26 % decrease in their position. The disclosure for this sale can be found here. 32.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group boosted their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Craig Hallum increased their target price on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, September 27th.

Bioventus Stock Down 0.4 %

BVS opened at $10.50 on Thursday. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The company has a market capitalization of $852.13 million, a P/E ratio of -17.21 and a beta of 0.79. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm’s fifty day moving average price is $11.72 and its two-hundred day moving average price is $9.90.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same quarter in the prior year, the business posted $0.05 earnings per share. On average, analysts anticipate that Bioventus Inc. will post 0.41 EPS for the current year.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.